The prevalence and prognostic impact of mutations promoting chromatin remodelling dysregulation in non-resectable or recurrent/metastatic adenoid cystic carcinoma
Affiliation
Christie Hospital NHS Foundation Trust, Manchester,Issue Date
2022
Metadata
Show full item recordCitation
Rack S, Feeney L, Mistry H, Betts G, Harrington KJ, Metcalf R. The prevalence and prognostic impact of mutations promoting chromatin remodelling dysregulation in non-resectable or recurrent/metastatic adenoid cystic carcinoma. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301789.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.6087Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.6087Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.6087